Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearbridge HealthFRA:5C6 10-Year RORE % is 4.17 as of Jun. 2026. The stock has 4 warning signs investors should review. Among 122 Medical Diagnostics & Research companies, Clearbridge Health ranks better than 59.02% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Clearbridge Health's 10-Year RORE % for the quarter that ended in Jun. 2026 was 4.17%.
The industry rank for Clearbridge Health's 10-Year RORE % or its related term are showing as below:
FRA:5C6's 10-Year RORE % is ranked better than 59.02% of 122
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.14
vs FRA:5C6: 4.17
Clearbridge Health (FRA:5C6) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Clearbridge Health 10-Year RORE % Related Terms
Clearbridge Health 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Clearbridge Health's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5C6 vs TMO, DHR, IDXX: 10-Year RORE % Comparison
For the Diagnostics & Research subindustry, Clearbridge Health's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearbridge Health 10-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clearbridge Health's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Clearbridge Health's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 10-year before.
Clearbridge Health (FRA:5C6) has a 10-Year RORE % of 4.17 as of Jun. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Clearbridge Health and its competitors. According to the industry distribution chart, Clearbridge Health ranks #50 out of 122 companies in the Medical Diagnostics & Research industry, placing it in the top 41%.
Is Clearbridge Health's 10-Year RORE % too high?
Clearbridge Health's current 10-Year RORE % is 4.17. Based on the distribution chart, Clearbridge Health ranks #50 out of 122 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Clearbridge Health's 10-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clearbridge Health ranks #50 out of 122 companies for 10-Year RORE %. This puts Clearbridge Health in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Diagnostics & Research company?
A good 10-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Clearbridge Health and its competitors. Clearbridge Health's current 10-Year RORE % is 4.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearbridge Health stock overvalued right now?
Clearbridge Health (FRA:5C6) has a current 10-Year RORE % of 4.17. The current 10-Year RORE % is 4.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Clearbridge Health (FRA:5C6), the current 10-Year RORE % is 4.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearbridge Health Ltd provides health care services. It is an integrated healthcare group with end-to-end diagnostic abilities, deploying non-invasive tests to identify and manage illness. The segments are Strategic investments; Others ; Medical clinics; Corporate segment and Investment. It derives key revenue from the Medical clinics segment. The medical clinics/centres segment involves the provision of general medical, dental and clinical services and distribution of the medical and pharmaceutical products. The group has a business presence in Singapore, Philippines, Hong Kong, Malaysia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5C6 has been successfully added to your 
